PRPH
ProPhase Labs, Inc. · Healthcare
ProPhase Labs, Inc. · Healthcare
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Healthcare
Drug Manufacturers - Specialty & Generic
96
1994-04-04
-0.32

Shares of ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.86 and traded as low as $0.0720. ProPhase Labs shares last traded at $0.0751, with a volume of 37,941 shares traded. Analysts Set New Price Targets

Institutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided a business update regarding its Crown Medical Collections initiative and related strategic activities.

Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today announced that it has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated esophageal cancer risk stratification test, and is advancing its Crown Medical Collections initiative, with each initiative independently offering the potential to drive significant liquidity and materially strengthen the Company's balance sheet.

UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings.

ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.12 and traded as low as $0.1740. ProPhase Labs shares last traded at $0.1998, with a volume of 490,748 shares traded. Analyst Upgrades and Downgrades Several equities
Abenante Carolina
director:
0 SH @ $0.00
2025-06-20
Karkus Ted William
director, officer: CEO & CHAIRMAN
500,000 SH @ $0.60
2025-09-09
Hollenshead Stuart
officer: Chief Operating Officer
500,000 SH @ $0.60
2025-02-17
Hollenshead Stuart
officer
0 SH @ $0.00
2025-01-27
Hirsch Warren
director
100,000 SH @ $0.60
2025-02-14
GLECKEL LOUIS MD
director
100,000 SH @ $0.60
2025-02-14
Karkus Ted William
director, 10 percent owner, officer: CEO & CHAIRMAN
400,000 SH @ $6.00
2024-03-17
Latkin Jed
director
500,000 SH @ $6.00
2024-01-01